Amino-acid derived regenerative therapy for reversing diabetes: L-Leucine, the branched chain essential amino acid, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 25/May/2017, 7.21 pm

Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: GDF11 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state via up-regulation of its target gene Lin28, 25/May/2017,7.17 am
May 25, 2017
Targeted Exercise mimetic therapy for Metabolic diseases: AICAR [5-aminoimidazole-4-carboxamide riboside] increases PPARδ levels, inhibits glucose catabolism, preserves glucose levels, stimulates FA catabolism, delays the onset of hypoglycemia and boosts endurance exercise via down regulation of its target gene, 25/May/2017, 8.11 am
May 25, 2017
Show all

Introduction: What they say

A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, California, USA; and Koch Institute at MIT, 500 Main Street, Cambridge, USA shows that “Fasting-Mimicking Diet Promotes Ngn3-Driven ß-Cell Regeneration to Reverse Diabetes.” This research paper was published in the 23 February 2017 issue of the journal “Cell” [One of the best research journals in Biology with an I.F of 28 plus] by Prof. and Director of Longevity institute Valter Longo, Cheng CW and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Amino acid regenerative therapy for reversing diabetes:L-Leucine, the branched chain essential amino acid, increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene 

Price 750


From Significance of the study to Public health relevance:

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) Diabetes is going to be one of the top 10 causes of death by 2030; (3) the life-long painful injection/drug treatment is required to treat DM; (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


What is known?

It has recently been shown that fasting mimicking diet (FMD):(1) increases the expression of Sox17, Pdx-1 (Pancreatic And Duodenal Homeobox 1), and Ngn3 (Neurogenin-3) sequentially; (2) promotes regeneration of insulin-producing ß cells; (3) decreases Protein Kinase A and mTOR activity; (4) increases reprogramming proteins Sox2 and Ngn3 expression; (5) increases insulin secretion; and (6) promotes glucose homeostasis, suggesting that FMD: (i) promotes reprogramming of pancreatic cells to restore insulin secretion in islets; and (ii) can reverse both T1D and T2D.


From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a natural product based regenerative therapy for T1D and TIID.

L-Leucine, by increasing the expression of its target genes, it may increase the expression of Sox17, Ngn3, Sox2, Pdx-1, NKX6.1, Pax6, INS etc. (Fig. 1). Thereby, it may: (1) decrease the expression of mTOR;  (2) increase generation of insulin-producing ß cells; (3) increase insulin secretion; and (4) promote glucose homeostasis, suggesting that L-Leucine–may replace the need for FMD or function as an effective alternative to FMD–may find its use in clinic in attenuating and/or reversing both T1D and T2D, as it turns on most of the reprogramming/insulin-producing genes turned by the FMD (Figs.1-3).

Figure 1. Mechanistic insights into how L-Leucine, by turning on the expression of Ngn3, NKX6.1, Pax6, and INS among others genes, may promote reprogramming of pancreatic cells to restore insulin secretion in islets; and reverse both T1D and T2D (fig1 was replaced on June 6, 2017).

 

Leucine க்கான பட முடிவு

Figure 2. The chemical structure of L-Leucine

Thus, pharmacological formulations encompassing “L-Leucine or its analogues either alone or in combination with other drugs/natural substances/compounds” may be used to treat and cure T1D and T2D.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does L-Leucine increase the expression of Sox17, Sox2, Pdx-1, and Ngn3 to reprogram of pancreatic cells, to restore insulin secretion?

Amount: $ 750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Amino-acid derived regenerative therapy for reversing diabetes: L-Leucine, the branched chain essential amino acid, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 25/May/2017, 7.21 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.